Lipid‐Lowering Efficacy and Safety After Switching to Atazanavir‐Ritonavir‐Based Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus

Abstract

Switching to an atazanavir-ritonavir-based HAART regimen was associated with significant improvement in lipid profiles, similar to those seen in clinical trials, without compromising safety or viral and immunologic control. In addition, more patients were able to achieve their NCEP ATP III goals.